

# 2024 REIMBURSEMENT GUIDE for

## PHYSICIAN OFFICE



Billing for  
Blue Light Cystoscopy  
with Cysview<sup>®</sup>  
(hexaminolevulinate hydrochloride)



THE  
BLADDER CANCER  
COMPANY

Cysview® (hexaminolevulinate hydrochloride) is an optical imaging agent.

- Indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder.
- Used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC®) as an adjunct to White Light Cystoscopy.
- Not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

## **Important Risk & Safety Information**

### **Limitations of Use**

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

### **Warnings and Precautions**

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.

### **Use in Specific Populations**

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.

### **Use of the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) System**

Cysview is approved for use with the KARL D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.

**Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.**

Photocure has developed the following reimbursement guidance for customers who perform Blue Light Cystoscopy in a physician office to report the use of Cysview® (hexaminolevulinate hydrochloride) to private commercial payers and Medicare.

The information contained in this guide is provided to help you understand the reimbursement process and is not intended to suggest any manner in which you can increase or maximize reimbursement from any payer. Reimbursement information is gathered from third-party sources and is subject to change. We recommend that you consult with payers for specific coverage and billing requirements.

## Disclaimers

The coding and payment data furnished in this guide is for general informational purposes only and should not be relied upon for purposes of determining payer coverage and coding for a specific case or claim for payment. This guide represents no promise, commitment, statement or guarantee by Photocure concerning proper billing or coding practices or levels of reimbursement, payment or charges. The materials referenced and provided are based upon coding experience and research of current general coding practices. The existence of codes does not guarantee coverage or payment for any procedure by any payer. The final decision for coding of any procedure must be made by the provider of care after considering the medical necessity of the services and supplies provided as well as the regulations and local, state, or federal laws that may apply.

All Current Procedural Terminology (CPT®) codes, Healthcare Common Procedural Coding System (HCPCS) codes, Ambulatory Payment Classifications (APCs) and National Drug Codes (NDC) are provided for your information only and Photocure does not represent that these codes are or will be appropriate or that reimbursement will be made if using them or any other codes. CPT® codes and descriptions only are copyrighted by the American Medical Association (AMA). CPT®, APC and other codes do not include fee schedules, relative values or related listings. The Centers for Medicare & Medicaid Services (CMS) updates coverage, coding and payment information frequently, and it is the responsibility of each health service provider to confirm the appropriate billing required by the local Medicare contractor.

Providers should refer to authoritative coding sources, such as the CPT® codes and HCPCS codes. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The information provided in this guide is for informational purposes only. Information included does not guarantee coverage or payment. Payment will vary by geographic locality. It is always the provider's responsibility to determine coding and claims information for the services that were provided.

CPT® copyright 2017 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

## 2024 Medicare Reimbursement

### Site of Service: Physician Office

Physicians who purchase Cysview for administration in the office setting are responsible for billing for the Cysview product in addition to the services provided by the physician. There is a unique HCPCS A code assigned to Cysview. Physicians should report HCPCS code A9589 (Instillation, hexaminolevulinate hydrochloride, 100mg) on a separate line on the claim form in addition to the CPT codes identifying the services provided to the patient on that date. The most appropriate CPT codes for the services performed should be reported on the claim.

The Medicare payment rate for HCPCS code A9589 is based on the Average Sales Price methodology updated quarterly by CMS. Wholesale Acquisition Cost or invoice price of Cysview. The 2024 payment rates for Blue Light Cystoscopy procedures performed in the office setting are included in this document. These procedures include CPT codes 52000, 52204, 52214 and 52224. CPT codes 52234, 52235 and 52240 are generally not performed in the office setting.

Please consult with your local MAC for specific coverage, coding and payment policies applicable to billing for Blue Light Cystoscopy procedures performed in the physician office setting.

## 2024 Private Payer Billing Guidance

Photocure recommends that you consult with payers for specific coverage and billing requirements.<sup>1</sup>

## Physician Office

Place of service code = 11



### Procedure codes

- Cystourethroscopy (52000)
- Cystourethroscopy with biopsy or higher (52204, 52214, 52224)



### What to bill

- Procedure code
- + A9589 for Cysview



### Commercial reimbursement

- Procedure and drug may be reimbursed separately
- Cysview at ASP + 6% to 15%



### Medicare reimbursement

- Procedure and drug are reimbursed separately
- Cysview at ASP + 6%

<sup>1</sup> Blue Light Cystoscopy with Cysview may be covered by private payers when medically necessary. Coverage guidelines and payment levels vary by payer and specific plan. Providers should contact each specific plan to determine coverage and payment.

**2024 Medicare Reimbursement**  
**Site of Service: Physician Office**

CPT® Code	Description	Physician Office Payment
52000	Cystourethroscopy (separate procedure)	\$235.43
52204	Cystourethroscopy, with biopsy(s)	\$370.34
52214	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands	\$730.52
52224	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or without biopsy	\$763.27

Actual payment will vary based on geographic adjustments less any applicable deductible, coinsurance, etc.

**Drug Code**

A9589	Instillation, hexaminolevulinate hydrochloride, 100 mg
-------	--

# Sample CMS-1500 Form for Physician Office Setting



## HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

<input type="checkbox"/> PICA		<input type="checkbox"/> PICA	
1. MEDICARE <input checked="" type="checkbox"/> (Medicare#) MEDICAID <input type="checkbox"/> (Medicaid#) TRICARE <input type="checkbox"/> (ID#/DoD#) CHAMPVA <input type="checkbox"/> (Member ID#) GROUP HEALTH PLAN <input type="checkbox"/> (ID#) FECA BLK LUNG <input type="checkbox"/> (ID#) OTHER <input type="checkbox"/> (ID#)		1a. INSURED'S I.D. NUMBER (For Program in Item 1) <b>123456789A</b>	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial) <b>JOHN DOE</b>		3. PATIENT'S BIRTH DATE MM DD YY <b>01 01 1950</b> SEX <input checked="" type="checkbox"/> M <input type="checkbox"/> F	
5. PATIENT'S ADDRESS (No., Street) <b>1234 MAIN ST</b>		6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>	
CITY <b>ANYWHERE</b> STATE <b>MA</b>		7. INSURED'S ADDRESS (No., Street)	
ZIP CODE <b>12345</b> TELEPHONE (Include Area Code) <b>(555) 555-1212</b>		CITY STATE ZIP CODE TELEPHONE (Include Area Code)	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) <b>NONE</b>		10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO b. AUTO ACCIDENT? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO PLACE (State) c. OTHER ACCIDENT? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO	
a. OTHER INSURED'S POLICY OR GROUP NUMBER		11. INSURED'S POLICY GROUP OR FECA NUMBER	
b. RESERVED FOR NUCC USE		a. INSURED'S DATE OF BIRTH MM DD YY SEX M <input type="checkbox"/> F <input type="checkbox"/>	
c. RESERVED FOR NUCC USE		b. OTHER CLAIM ID (Designated by NUCC)	
d. INSURANCE PLAN NAME OR PROGRAM NAME		c. INSURANCE PLAN NAME OR PROGRAM NAME	
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below. SIGNED _____ DATE _____		d. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO If yes, complete items 9, 9a, and 9d. 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below. SIGNED _____	
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL.		15. OTHER DATE MM DD YY QUAL.	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE		17a. NPI	
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY	
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. A. <b>C67.1</b> B. C. D. E. F. G. Code H. I. J. K. L.		18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY	
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROC (Exp CPT/HC) E. NOSIS ENTER		20. OUTSIDE LAB? <input type="checkbox"/> YES <input type="checkbox"/> NO \$ CHARGES	
25. FEDERAL TAX I.D. NUMBER <b>222222</b> SSN EIN <input type="checkbox"/> <input checked="" type="checkbox"/> X		22. RESUBMISSION CODE ORIGINAL REF. NO.	
26. PATIENT'S ACCOUNT NO. <b>P1111</b>		23. PRIOR AUTHORIZATION NUMBER	
27. ACCEPT ASSIGNMENT? (For govt. claims, see back) <input type="checkbox"/> YES <input type="checkbox"/> NO		F. \$ CHARGES G. DAYS OR UNITS H. EPSDT Family Plan I. ID. QUAL. J. RENDERING PROVIDER ID. #	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) SIGNED _____ DATE _____		28. TOTAL CHARGE \$ <b>\$XXXX XX</b> 29. AMOUNT PAID \$ 30. Rsvd for NUCC Use	
32. SERVICE FACILITY LOCATION INFORMATION <b>OFFICE 1234 1 ST MA</b>		33. BILLING PROVIDER INFO & PH # ( ) <b>OFFICE 1234 1 ST MA</b>	
a. <b>2222222</b> b.		a. <b>2222222</b> b.	

Code for primary procedure performed.

Establishing charges is the responsibility of the provider. Any dollar figures mentioned in this document are examples only and are not intended to suggest actual amounts that should be charged.

**2024 Medicare Reimbursement  
Relative Value Units – Office (POS 11)**

CPT® Code	Work RVU	Practice Expense RVU	Malpractice RVU
52000	1.53	5.47	0.19
52204	2.59	8.40	0.32
52214	3.50	18.39	0.42
52224	4.05	18.77	0.49

Photocure is pleased to offer toll-free customer support and documentation for coding and reimbursement related to Cysview.

For additional questions, please contact Photocure's reimbursement helpline at  
**1-855-CYSVIEW (1-855-297-8439)**

## Cysview Website

For more information regarding Cysview please visit our website:

**[Cysview.com](https://www.cysview.com)**

